A question that keeps surfacing in PDRN communities: is Rejuran the only real PDRN, and are all the other products on the market generic replicas of dubious quality? The question has become more prominent as dozens of new PDRN products have launched, and as claims circulate online that Rejuran's parent company holds exclusive rights to the ingredient.
The reality is more nuanced — and understanding it matters if you are trying to make a sensible decision about what you are actually buying.
Go deeper
The Complete Guide covers PDRN sources, concentrations, and how to read a product label.
46 pages. No product recommendations. $12.What Rejuran Actually Is
Rejuran is a brand name — specifically a line of products made by PharmaResearch Co., a South Korean pharmaceutical company. Their injectable skin booster product, Rejuran Healer, was one of the first commercially successful PDRN-based aesthetic treatments and is what drove the original wave of interest in PDRN as a skincare ingredient.
PharmaResearch holds patents on specific formulations and production processes related to their PDRN preparations. This is standard pharmaceutical practice — companies patent their specific methods and formulations, not the underlying molecule itself. PDRN (polydeoxyribonucleotide) as a molecule has been used in pharmaceutical products since the 1980s, originally developed in Italy. It is not and has never been exclusively owned by any single company.
What "Generic PDRN" Means
Other companies producing PDRN products — whether injectable preparations sold at Korean pharmacies or cosmetic serums — are not necessarily producing inferior products. They are producing their own formulations using the same general ingredient category, not copies of Rejuran's specific patented formulation.
The concern raised in some communities is that the approval process for generic pharmaceutical preparations in Korea is less rigorous than in the EU, potentially allowing products with inconsistent quality to reach market. This is a legitimate regulatory concern — but it applies to manufacturing quality and consistency standards, not to whether PDRN from other sources can work.
The PDRN molecule itself — polydeoxyribonucleotide derived from salmon or trout — activates the A2A adenosine receptor regardless of which company extracted it, provided the extraction and purification process meets quality standards. The mechanism does not belong to Rejuran.
What Actually Differentiates Products
The meaningful differences between PDRN products are not brand vs generic. They are concentration, purity of extraction, formulation stability, and delivery format. A well-manufactured PDRN product at 1,000 ppm from a reputable pharmaceutical producer is doing the same biological thing as Rejuran at the same concentration. A poorly manufactured product with inconsistent PDRN content, regardless of brand name, is not.
For injectable clinical treatments, the stakes of quality consistency are higher — and choosing a clinic that uses established, well-sourced preparations matters more than it does for topical cosmetics. For topical products, the more practical questions are whether PDRN appears at a meaningful concentration, whether the formulation is stable, and whether it is manufactured by a reputable producer — not which brand name is on the packaging.
The Honest Bottom Line
Rejuran is a well-researched, reputable product with a long track record, particularly for injectable treatments. It is not the only legitimate source of PDRN. The suggestion that all non-Rejuran PDRN is a generic replica of lesser quality conflates a specific patented formulation with the entire ingredient category — which is inaccurate. What matters for any PDRN product is manufacturing quality, concentration transparency, and formulation — not the brand name.
PDRNSkinLab Report